Depomed (DEPO) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Leerink Keeps Depomed (DEPO) at 'Outperform'; Disappointing Q3 Steps-up Pressure to Sell
November 8, 2016 11:00 AM ESTLeerink affirms its Outperform rating and $22 price target on Depomed (Nasdaq: DEPO) following Q3 results and update on Monday night.
Analyst Jason M. Gerberry commented today, DEPO reported disappointing 3Q results, missing our/Streets revenue forecasts by 13% and reducing 2016 revenue guidance for the third consecutive qtr. The miss... More
Cantor Fitzgerald Downgrades DepoMed Inc (DEPO) to Hold
November 8, 2016 7:41 AM ESTCantor Fitzgerald downgraded DepoMed Inc (NASDAQ: DEPO) from Buy to Hold with a price target of $23.00 (from $25.00).
For an analyst ratings summary and ratings history on DepoMed Inc click here. For more ratings news on DepoMed Inc click here.
Shares of DepoMed Inc closed at $22.89 yesterday.
... More